Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004638 · ClinicalTrials.gov registry record · Phase 2
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03004638 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 32 participants.
The verdict
NCT03004638, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of MEDI6012 in subjects with stable atherosclerosis.
Interventions
- DRUG Placebo
- DRUG MEDI6012 40 mg
- DRUG MEDI6012 120 mg
- DRUG MEDI6012 300 mg
- DRUG Placebo IV Push
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2017-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004638
The ClinicalTrials.gov registry entry for NCT03004638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03004638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03004638 about?
NCT03004638 is a clinical study titled "Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease". To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of MEDI6012 in subjects with stable atherosclerosis.
What is the current status of trial NCT03004638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-01-23. Estimated completion is 2017-11-02.
What interventions are being tested in trial NCT03004638?
The interventions under investigation include: Placebo (DRUG), MEDI6012 40 mg (DRUG), MEDI6012 120 mg (DRUG), MEDI6012 300 mg (DRUG), Placebo IV Push (DRUG).
Who is sponsoring clinical trial NCT03004638?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.